- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
CorEvitas Acquires Pregnancy Data Registry Pregistry
This is the intelligence company's fifth acquisition.
CorEvitas announced the acquisition of Pregistry LLC, a company focused on safety studies during pregnancy.
Pregistry utilizes 70 pregnancy experts to provide reports and studies on healthy pregnancies and births. The group collects data based on clinical, safety, regulatory, marketing, and technology needs and is then shared with individuals, providers, and industry stakeholders. This information is reportedly used by doctors as part of their decisions on what medications and vaccines to prescribe.
In a press release, Dr. Diego Wysznski, founder and chief executive officer of Pregistry, said, “For the last eight years, Pregistry has been a leader in the design and execution of pregnancy exposure registries to fulfill global regulatory commitments, such as mandates from the FDA and the EMA, and other observational studies in the maternal health field, including the world's largest pregnancy registries on COVID-19 vaccines and Covid treatments.”
CorEvitas is an intelligence company to provides a syndicated network of registries. Pregistry is its fifth acquisition.
Continue reading this story here.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
